Cytune Pharma Secures EUR 6M in Financing to Advance Lead Immuno-Oncology Program to Phase I
(firmenpresse) - NANTES, FRANCE -- (Marketwired) -- 06/29/16 --
Cytune''s lead product RLI15 and its platform, based on a modified and improved IL-15, allow for combinations with other immunotherapeutic strategies, including checkpoint inhibitors. RLI15, due to its unique mode of action, has been proven to stimulate immune effector cells, such as cytotoxic and helper T cells, as well as NK cells, but does not stimulate the immune-inhibitory regulatory T cells or other cells. As established in pre-clinical experiments, RLI15 is more potent and better tolerated compared to the normal IL15 or IL2.
PPF Group and other existing investors participated in the financing. The funds will enable Cytune to advance RLI15 to Phase I clinical trials in 2017 and broaden its immunocytokine product pipeline based on RLI15. Cytune Pharma and SOTIO, a biotechnology company experienced in the clinical development of oncology products and a member of PPF Group, will closely collaborate on the further development of Cytune''s pipeline.
Dr David Bechard, President of Cytune Pharma commented:
"Our innovative products have the potential to provide more efficacious and safer treatments to cancer patients, when used either as monotherapy or for augmenting immunotherapies currently on the market. We are very grateful for the continuous and strong support of our shareholders."
Ladislav Bartonicek, shareholder of PPF and CEO of SOTIO, commented:
"We are very pleased with the latest data and progress of the Cytune projects, as well as the diligence with which the team advances RLI15 towards its first clinical trials. We are looking forward to moving RLI15 through clinical development to be able to offer superior alternative treatments to cancer patients."
Link to full release:
Contacts:
RNS
Customer Services
0044-207797-4400
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.06.2016 - 10:27 Uhr
Sprache: Deutsch
News-ID 1444429
Anzahl Zeichen: 3690
contact information:
Contact person:
Town:
NANTES, FRANCE
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 230 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytune Pharma Secures EUR 6M in Financing to Advance Lead Immuno-Oncology Program to Phase I
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytune Pharma SAS (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
